Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alterity Therapeutics (ATHE) Short-term Investments (2017 - 2025)

Alterity Therapeutics has reported Short-term Investments over the past 1 years, most recently at $120498.3 for Q4 2017.

  • For Q4 2017, Short-term Investments changed N/A year-over-year to $120498.3; the TTM value through Dec 2017 reached $120498.3, changed N/A, while the annual FY2017 figure was $112681.5, N/A changed from the prior year.
  • Short-term Investments for Q4 2017 was $120498.3 at Alterity Therapeutics, up from $112681.5 in the prior quarter.
  • Over five years, Short-term Investments peaked at $120498.3 in Q4 2017 and troughed at $112681.5 in Q2 2017.